Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Cancers (Basel) ; 16(9)2024 Apr 24.
Article in English | MEDLINE | ID: mdl-38730583

ABSTRACT

(1) Background: Minimally invasive surgery (MIS) represents a feasible approach in early-stage ovarian cancer, while this question is still unsolved for advanced and recurrent disease. (2) Methods: In this retrospective, multicenter study, we present a series of 21 patients who underwent MIS for primitive or recurrent epithelial ovarian cancer (EOC) with bulky nodal metastasis and discuss surgical technique and outcomes in relation to the current literature. (3) Results: Complete cytoreduction at primary debulking surgery was obtained in 86% of cases. No complication occurred in our patients intraoperatively and only 11.1% of our patients experienced grade 2 and 3 postoperative complications. Notably, all the patients with isolated lymph nodal recurrence (ILNR) were successfully treated with a minimally invasive approach with no intra- or postoperative complications. (4) Conclusions: The results of our study are consistent with those reported in the literature, demonstrating that MIS may represent a safe approach in advanced and recurrent EOC with nodal metastasis if performed on selected patients by expert surgeons with an adequate setting and appropriate technique.

2.
Int J Gynecol Cancer ; 27(9): 1863-1871, 2017 11.
Article in English | MEDLINE | ID: mdl-28763363

ABSTRACT

OBJECTIVE: The present study assessed the predictive value of age and Modified Frailty Index (mFI) on the management of primary epithelial ovarian cancer (EOC) patients aged 70 years or older (elderly). METHODS: A retrospective multicenter study selected elderly EOC patients treated between 2006 and 2014. Treatments were analyzed according to the following age group categories: (1) 70 to 75 years versus (2) older than 75 years, and mFI of less than 4 (low frailty) versus greater than or equal to 4 (high frailty). RESULTS: Seventy-eight patients were identified (40 in age group 1 and 38 in age group 2). The mFI was greater than or equal to 4 in 23 women. Median age of low frailty and high frailty was not significantly different (75.6 vs 75.3). Comorbidities were equally distributed according to age, whereas diabetes, hypertension, obesity, and chronic renal failure were more frequent in the high-frailty group. Performance status was different only according to mFI. Twenty percent of age group 1 versus 55.3% of age group 2 underwent none or only explorative surgical approach (P = 0.003), whereas surgical approaches were similar in the 2 frailty groups. The rate of postoperative complications was higher in high-frailty patients compared with low-frailty patients (23.5% vs 4.3%; P = 0.03). Chemotherapy was administered to all the patients, a monotherapy regimen to 50% of them. No differences in toxicity were registered, except more hospital recovery in the high-frailty cohort. Median survival time was in favor of younger patients (98 versus 30 months) and less-frailty patients (56 vs 27 months). CONCLUSIONS: Elderly EOC patients can receive an adequate treatment, but patients who are older than 75 years can be undertreated, if not adequately selected. The pretreatment assessment of frailty through mFI could be suggested in the surgical and medical management.


Subject(s)
Neoplasms, Glandular and Epithelial/drug therapy , Neoplasms, Glandular and Epithelial/surgery , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/surgery , Age Factors , Aged , Aged, 80 and over , Carcinoma, Ovarian Epithelial , Female , Frail Elderly , Geriatric Assessment , Humans , Retrospective Studies , Treatment Outcome
3.
Anticancer Res ; 37(8): 4005-4015, 2017 08.
Article in English | MEDLINE | ID: mdl-28739682

ABSTRACT

Lower body lymphedema is a chronic condition and a significant cause of morbidity following treatment of gynecologic cancer that strongly impacts patients' quality of life (QoL). Most studies on secondary lymphedema have been performed on the upper limb after breast cancer treatment and much less is known about lower body lymphedema after gynecologic malignancies. This review focuses on secondary lymphedema due to gynecologic cancer treatment, analyzing its incidence in the different types of gynecologic cancer, diagnosis, risk factors, impact on QoL and treatment. A systematic search of Medline has been performed to track the studies evaluating lower body lymphedema after treatment for endometrial, ovarian, cervical and vulvar cancer. Unfortunately, there is no consensus about a uniform evaluation and, as a consequence, the reported incidence is broadly different among the studies. Standardization in lymphedema evaluation is required to better compare the outcome of different types of treatment.


Subject(s)
Genital Neoplasms, Female/complications , Genital Neoplasms, Female/therapy , Lower Extremity/physiopathology , Lymphedema/physiopathology , Female , Genital Neoplasms, Female/physiopathology , Humans , Lymph Node Excision/adverse effects , Lymphedema/classification , Lymphedema/diagnosis , Lymphedema/etiology , Quality of Life , Risk Factors
4.
Support Care Cancer ; 23(11): 3157-63, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25805450

ABSTRACT

OBJECTIVE: Malignant bowel obstruction (MBO) is usually a pre-terminal event in patients with ovarian cancer. However, because of the lack of data in literature, decisions around surgical intervention, non-resectional procedures, or medical treatment of MBO in patients with ovarian cancer cannot be lightly undertaken. We analyzed medical and surgical procedures, performance status, nutritional status, cachexia, and their prognostic value in this group of patients. METHODS: We retrospectively selected all consecutive patients with recurrent ovarian cancer who received medical or surgical treatment for MBO between October 2008 and January 2014 at the Academic Department of Gynecological Oncology of Mauriziano Hospital of Turin (Italy). RESULTS: We found 40 patients: 18 of them underwent medical treatment and 22 of them were submitted to surgery. In the group of surgery, the hospitalization was shorter (p 0.02), the pain reduction was more effective (p 0.001), the number of chemotherapy lines was higher (p 0.03), and re-obstruction was more rare (p 0.02). Between the two groups, we did not find any differences in post-palliation episodes of vomit (p 0.83), type of diet (p 0.34), ability to return home (p 0.72), and death setting (p 0.28). Median survival after palliation was longer in the group of surgery (p 0.025). Cachexia, low performance status, and poor nutritional status were significant predictors of worse survival after MBO, independently by the treatment. CONCLUSIONS: Surgery has to be considered in patients without serious contraindications; otherwise, a medical protocol, including antisecretory drugs, is the standard of care in frail patients.


Subject(s)
Intestinal Obstruction/surgery , Neoplasms, Glandular and Epithelial/complications , Ovarian Neoplasms/complications , Palliative Care/methods , Adult , Aged , Cachexia/drug therapy , Carcinoma, Ovarian Epithelial , Female , Humans , Intestinal Obstruction/etiology , Italy , Middle Aged , Neoplasms, Glandular and Epithelial/mortality , Ovarian Neoplasms/mortality , Pain/drug therapy , Prognosis , Recurrence , Retrospective Studies , Young Adult
5.
Int J Gynecol Cancer ; 25(3): 521-5, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25621410

ABSTRACT

OBJECTIVE: Lymphadenectomy is a frequent procedure for surgical staging of gynecological malignancies. Nevertheless, minor complications, such as lower limb lymphedema (LLL) and neurological complications (NCs), after pelvic and aorto-caval lymphadenectomy still remain underinvestigated. The present study considers short-term and long-term incidence and risk factors for LLL and NC in patients with gynecological cancer who underwent lymphadenectomy. MATERIALS AND METHODS: In 2 different institutions, University of Turin and University of Lausanne, a total of 152 patients who received lymphadenectomy for endometrial, cervical, or ovarian cancer were retrospectively identified. During the follow-up, data about LLL and NC were collected by means of a questionnaire. Short-term and long-term incidence of LLL and NC was evaluated, and risk factors, such as age, body mass index, type of cancer, surgical approach, number and extension of the removed lymph nodes, presence of lymph node metastasis, and adjuvant treatments, were analyzed. RESULTS: Short-term incidence of LLL and NC after lymphadenectomy was high (36%) and predictive of long-term persistence. Between the analyzed risk factors, number of removed lymph nodes and adjuvant radiotherapy were significantly associated with an increased incidence of minor complications (P < 0.05). CONCLUSIONS: Lower limb lymphedema and NC are more frequent than expected. They are related to the radicality of lymphadenectomy and adjuvant radiotherapy. They affect the quality of life of the patients treated for gynecological cancer and their perceptions of healing. Minor complications are commonly persistent and need a prompt diagnosis and a specialized management to improve their prognosis.


Subject(s)
Genital Neoplasms, Female/therapy , Lumbosacral Plexus/injuries , Lymph Node Excision/adverse effects , Lymphedema/epidemiology , Peripheral Nerve Injuries/complications , Peripheral Nervous System Diseases/epidemiology , Adult , Aged , Aged, 80 and over , Female , Humans , Incidence , Lower Extremity , Lymphedema/etiology , Middle Aged , Peripheral Nervous System Diseases/etiology , Radiotherapy, Adjuvant/adverse effects , Risk Factors , Time Factors
6.
Tumori ; 99(2): 204-9, 2013.
Article in English | MEDLINE | ID: mdl-23748815

ABSTRACT

AIMS AND BACKGROUND: Hysteroscopic polypectomy is the gold standard to treat endometrial polyps and obtain specimens for histological evaluation. There is continuing debate as to when to offer hysteroscopic polypectomy, especially in asymptomatic women with incidental lesions. The aims of this study were to assess the accuracy of hysteroscopy and Vabra sampling in diagnosing atypical hyperplasia and cancer growing on the surface of endometrial polyps and to investigate the association between atypical endometrial polyps and some potential clinical risk factors. METHODS AND STUDY DESIGN: This was a retrospective study. We assessed 1039 hysteroscopies and we identified 345 women with endometrial polyps. All patients with endometrial polyps underwent hysteroscopic polypectomy. Data about age, menopausal status, abnormal uterine bleeding (AUB), hormone replacement therapy and tamoxifen use were collected. Hysteroscopic, histological and clinical data were analyzed. RESULTS: The incidence of endometrial hyperplasia or cancer growing on the surface of endometrial polyps was significantly low (1.7%). Hysteroscopy correctly excluded (negative predictive value: 100%) and accurately predicted (positive predictive value: 85.7%) preneoplastic or neoplastic lesions growing within the epithelial layer of endometrial polyps. Vabra sampling was inadequate for the histological diagnosis in 38.5% of cases. Age over 60 years and postmenopausal AUB were associated with an 8.3-fold ( P = 0.022) and 8.8-fold (P = 0.020) increased risk, respectively, of preneoplastic and neoplastic lesions growing on the surface of endometrial polyps. CONCLUSIONS: Diagnostic hysteroscopy is a good tool to predict malignancy of the epithelial layer of endometrial polyps. Age over 60 years and AUB are associated with an increased risk of malignant polyps. Few suspicious endometrial polyps should undergo surgical resection.


Subject(s)
Adenocarcinoma/diagnosis , Endometrial Hyperplasia/diagnosis , Endometrial Neoplasms/diagnosis , Hysteroscopy , Polyps/diagnosis , Precancerous Conditions/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Diagnosis, Differential , Endometrial Hyperplasia/pathology , Endometrial Hyperplasia/surgery , Endometrial Neoplasms/pathology , Endometrial Neoplasms/surgery , Female , Humans , Middle Aged , Polyps/pathology , Polyps/surgery , Precancerous Conditions/pathology , Precancerous Conditions/surgery , Predictive Value of Tests , Retrospective Studies , Uterine Diseases/diagnosis
7.
Int J Gynecol Cancer ; 19(9): 1529-34, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19955931

ABSTRACT

OBJECTIVES: Most patients with ovarian cancer are candidates for second-line or salvage treatments often for prolonged periods. Patients with platinum-sensitive disease can benefit from a platinum retreatment with a likelihood of response dependents on the treatment-free interval. Alternative agents and combination chemotherapy are potential therapeutic approaches. At our institution, we carried out a phase II trial to evaluate feasibility, efficacy, and toxicity of gemcitabine and vinorelbine combination in recurrent ovarian carcinoma. The aim of the present study was to evaluate the role of this combination in patients with platinum-sensitive disease. PATIENTS AND METHODS: Patients with platinum-sensitive disease recurring after 1 or more lines of platinum-based chemotherapy were included. Vinorelbine at 25 mg/m followed by gemcitabine at 1000 mg/m was administered intravenously on days 1 and 8 every 3 weeks. Response Evaluation Criteria in Solid Tumors and cancer antigen 125 test (CA-125 Kinetics [Rustin criteria]) were adopted to classify responses. Toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria. RESULTS: Thirty-nine patients were eligible. Platinum-free interval (PFI) was 6 to 12 months in 13 patients (33.3%; PFI 6-12) and more than 12 months in 26 patients (66.7%; PFI > 12). The overall response rate was 48.7%, with 6 complete responses. Median response duration was 38 weeks. The response rate was 23% in PFI 6-12 and 62% in PFI >12. The most frequently observed toxicity was hematological, with 23% of the patients having grade 3 or 4 neutropenia. CONCLUSIONS: Gemcitabine and vinorelbine combination is effective and well tolerated in recurrent platinum-sensitive ovarian cancer. It may represent an option in the management of these patients because the chronic nature of the disease.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Papillary/drug therapy , Deoxycytidine/analogs & derivatives , Drug Resistance, Neoplasm/drug effects , Ovarian Neoplasms/drug therapy , Platinum Compounds/pharmacology , Vinblastine/analogs & derivatives , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Papillary/mortality , Carcinoma, Papillary/pathology , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Feasibility Studies , Female , Humans , Middle Aged , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Platinum Compounds/therapeutic use , Recurrence , Survival Analysis , Vinblastine/administration & dosage , Vinblastine/adverse effects , Vinorelbine , Gemcitabine
8.
Córdoba; Universitas; 1a. ed; 2004. 254 p. Ilus, tab, mapas.
Monography in Spanish | BINACIS | ID: bin-140603

ABSTRACT

Se describen los principales aspectos relativos a la geografía física, el proceso de urbanización, la evolución del drenaje urbano y la problemática de las inundaciones en áreas urbanas de distintas regiones de la Argentina. Se incluye el análisis de una serie de casos destacados relativos a inundaciones ocurridas en los últimos años en diversas ciudades del país


Subject(s)
Floods , Hydrologic Disaster , Flood Control , Drainage, Sanitary , Environment , Urbanization
9.
Córdoba; Universitas; 1a. ed; 2004. 254 p. ilus, tab, map.
Monography in Spanish | BINACIS | ID: biblio-1221934

ABSTRACT

Se describen los principales aspectos relativos a la geografía física, el proceso de urbanización, la evolución del drenaje urbano y la problemática de las inundaciones en áreas urbanas de distintas regiones de la Argentina. Se incluye el análisis de una serie de casos destacados relativos a inundaciones ocurridas en los últimos años en diversas ciudades del país


Subject(s)
Flood Control , Hydrologic Disaster , Drainage, Sanitary , Floods , Environment , Urbanization
SELECTION OF CITATIONS
SEARCH DETAIL
...